Unregistered
02-22-2006, 02:18 PM
More on Herceptin.
RB
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525711B00713623
Interim Combined Analysis Shows Benefits of Adjuvant trastuzumab (Herceptin) in HER2-positive Early Breast Cancer: Presented at IBCEF
ABSTRACT
At a median follow-up of 2 years, this combined analysis showed a significant benefit of trastuzumab (AC-PT) over AC-P for disease-free survival (DFS) of 85% versus 67% (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.39-0.59; P < .0001). Dr Perez also indicated that this significant improvement in DFS for AC-PT was seen across all subgroups analysed, which included tumour size and per protocol, although it was lost for the patients with no positive nodes.
For time to first distant recurrence, there were significant improvements seen in the trastuzumab group versus paclitaxel -- 90% and 74% (HR, 0.47; 95% CI, 0.37-0.61; P < .0001). This was also the case for overall survival -- 91% and 87% (HR, 0.67; 95% CI, 0.48-0.93; P = .015), respectively.
RB
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525711B00713623
Interim Combined Analysis Shows Benefits of Adjuvant trastuzumab (Herceptin) in HER2-positive Early Breast Cancer: Presented at IBCEF
ABSTRACT
At a median follow-up of 2 years, this combined analysis showed a significant benefit of trastuzumab (AC-PT) over AC-P for disease-free survival (DFS) of 85% versus 67% (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.39-0.59; P < .0001). Dr Perez also indicated that this significant improvement in DFS for AC-PT was seen across all subgroups analysed, which included tumour size and per protocol, although it was lost for the patients with no positive nodes.
For time to first distant recurrence, there were significant improvements seen in the trastuzumab group versus paclitaxel -- 90% and 74% (HR, 0.47; 95% CI, 0.37-0.61; P < .0001). This was also the case for overall survival -- 91% and 87% (HR, 0.67; 95% CI, 0.48-0.93; P = .015), respectively.